Table 6.

Differences in patient reported outcomes (PROs) at baseline and after 12 weeks for the full analysis set (n=38).

PROs		Baseline	Week 12	Change from baseline to week 12	P valuea
EQ-5D-5L indexb		0.8 (0.7 to 0.9)	0.9 (0.8 to 1.0)	0.0 (–0.1 to 0.0)	.36
DASS-21c, median (IQR)
	Total score (0 to 56)	5.5 (2.0 to 13.0)	6.0 (2.0 to 11.0)	0.0 (–2.0 to 2.0)	.95
	Depression score	1.0 (0.3 to 4.5)	1.0 (0.0 to 3.0)	0.0 (0.0 to 1.0)	—d
	Anxiety score	1.0 (0.0 to 2.0)	1.0 (0.0 to 2.0)	0.0 (–0.7 to 1.0)	—
	Stress score	3.0 (1.0 to 6.0)	3.0 (0.3 to 6.0)	0.0 (–1.0 to 1.0)	—
MMAS-8e
	Total score (0 to 8)	7.0 (6.8 to 8.0)	7.0 (6.8 to 8.0)	0.0 (–0.7 to 0.0)	.68
	High adherence (=8), n (%)	14 (37)	15 (39)	N/Af	—
	Moderate adherence (6 to 7), n (%)	15 (39)	15 (39)	N/A	—
	Low adherence (<6), n (%)	9 (24)	8 (21)	N/A	—

^aAnalyzed with Wilcoxon signed-rank test.

^bEQ-5D-5L index: EuroQol-5 Dimension – 5-Level index.

^cDASS-21: Depression, Anxiety, and Stress Scale - 21 Items.

^dNot available.

^eMMAS-8: 8-item Morisky Medication Adherence Scale.

^fN/A: not applicable.